
|Articles|December 3, 2018
Novel treatments in pipeline for diabetic eye disease
Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.
Advertisement
Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
Alvotech files first known aflibercept 8 mg biosimilar with EMA
3
Duravyu misses noninferiority end point in phase 3 LUCIA wet AMD trial
4
FDA approves subcutaneous Enspryng for TED
5

















